

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete If Known Application Number Not Yet Assigned Filing Date April 14, 2004 First Named Inventor Göran Bondjers Art Unit Not Yet Assigned Examiner Name Not Yet Assigned Attorney Docket Number ASZD-P02-029	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				
Sheet	1	of	2	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JK/	AA	US-5,260,440	11-09-1993	Hirai et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	* ⁶
/JK/	BA	WO-9802357-A1	01-22-1998	Astra Aktiebolag		
/JK/	BB	WO-9911260-A1	03-11-1999	Pfizer Inc.		
/JK/	BC	WO-9738694-A1	10-23-1997	Merck & Co., Inc.		
/JK/	BD	WO-0038725-A1	07-06-2000	G.D. Searle & Co.		
/JK/	BE	WO-0197751-A2	12-27-2001	AstraZeneca AB		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application related upon in this application for an earlier filing date under 35 U.S.C. 120. * Applicant's unique citation designation number (optional). * See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			* ²
/JK/	CA	Eagles, C.J., et al. The effects of combined treatment with beta 1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects*. Br. J. Clin. Pharmacol. 43(3) 291-300 (1997).			
/JK/	CB	Foss, O., et al. Treatment of hypertensive and hypercholesterolaemic patients in general practice. Scand J Print Health Care, 17, 122-127 (1999).			
/JK/	CC	Pool, J., et al. Lovastatin and Coadministered Antihypertensive/Cardiovascular Agents. Hypertension, 19(3), 242-248 (1992).			
/JK/	CD	Witchitz, S., et al. Effets comparés du captopril et de l'aténolol sur le métabolisme lipidique chez des patients hypertendus hypercholestérolémiques traités par pravastatine. Presse Med, 25(40), 2013-2016 (1996).			
/JK/	CE	Garnett, W. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm, Vol. 52, 1639-1645 (1995).			
/JK/	CF	Berglund, G., et al. W-3 Imaging of Atherosclerosis: Low dose metoprolol and fluvastatin slow progression of atherosclerosis: Main results from BCAPS. XIIth International Symposium on Atherosclerosis, Stockholm, Sweden, June 25-29, 2000, 151(1), 4 (2000).			
/JK/	CG	Hedblad, B., et al. W-3 Imaging of Atherosclerosis: Low dose metoprolol and fluvastatin in silent atherosclerotic disease: Metabolic and adverse effects in BCAPS. XIIth International Symposium on Atherosclerosis, Stockholm, Sweden, June 25-29, 2000, 151(1), 24 (2000).			
/JK/	CH	Westergren, G., et al. Effective Once-Daily Treatment of Hypertension with Low-Dose, Controlled Release Metoprolol, Pooled Results from Three Randomized, Double-Blind, Placebo-Controlled Studies. Current Therapeutic Research 55(2), 142-148 (1994).			
/JK/	CI	Kaplan, J.R., et al. The effects of beta-adrenergic blocking agents on atherosclerosis and its complications. European Heart Journal, 8, 928-944 (1987).			

Examiner Signature	/Jennifer Kim/	Date Considered	04/30/2006
--------------------	----------------	-----------------	------------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	April 14, 2004
				First Named Inventor	Göran Bondjers
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	ASZD-P02-029
Sheet	2	of	2		

/JK/	CJ	Ostlund-Lindqvist, A. Effect of Metoprolol on Diet-Induced Atherosclerosis in Rabbits. Arteriosclerosis, 8(1), 40-45 (1988).	
/JK/	CK	Ablad, B., et al. The role of sympathetic activity in atherogenesis: Effects of beta-blockade. American Heart Journal, 116, 322-327 (1988).	
/JK/	CL	Sanderson, J., et al. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br. Heart J, 74, 502-507 (1995).	
/JK/	CM	Oestlund-Lindqvist et al., "Effect of metoprolol on plasma lipids and arterial intimal lipid deposition in spontaneously hypertensive rats," Atherosclerosis (Shannon Ireland) 80(2):135-142 (1989)	
/JK/	CN	Dorland's Illustrated Medical Dictionary, 28th Edition, page 795 (1994)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jennifer Kim/	Date Considered	04/30/2008
-----------------------	----------------	--------------------	------------